Drugs / DV202B1-RNA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07390474 | Mar 2026 → Dec 2027 expected | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DV202B1-RNA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07390474 ↗ |
| Modality | Messenger RNA (mRNA) | “Both vaccines consist of a modified mRNA encapsulated in lipid nanoparticles (LNP) that when translated in cells produces HIV-1 Env gp150 transmembrane trimers.” NCT07390474 ↗ |
| Route | Intramuscular | “To be administered intramuscularly as a split dose.” NCT07390474 ↗ |